Marker Therapeutics, Inc. (MRKR): Price and Financial Metrics


Marker Therapeutics, Inc. (MRKR): $0.32

0.01 (+4.59%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MRKR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MRKR Stock Summary

  • MRKR has a higher market value than just 9.03% of US stocks; more precisely, its current market capitalization is $29,008,918.
  • With a year-over-year growth in debt of -35.76%, MARKER THERAPEUTICS INC's debt growth rate surpasses merely 8.45% of about US stocks.
  • Revenue growth over the past 12 months for MARKER THERAPEUTICS INC comes in at 459.4%, a number that bests 97.8% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to MRKR, based on their financial statements, market capitalization, and price volatility, are TFFP, ITOS, STRO, FUSN, and SLDP.
  • Visit MRKR's SEC page to see the company's official filings. To visit the company's web site, go to www.markertherapeutics.com.

MRKR Valuation Summary

  • MRKR's price/sales ratio is 11.8; this is 521.05% higher than that of the median Healthcare stock.
  • MRKR's price/sales ratio has moved NA NA over the prior 73 months.

Below are key valuation metrics over time for MRKR.

Stock Date P/S P/B P/E EV/EBIT
MRKR 2022-11-01 11.8 1.3 -0.9 -0.5
MRKR 2022-10-31 12.4 1.3 -0.9 -0.6
MRKR 2022-10-28 12.4 1.3 -0.9 -0.6
MRKR 2022-10-27 12.5 1.3 -0.9 -0.6
MRKR 2022-10-26 12.5 1.3 -0.9 -0.6
MRKR 2022-10-25 12.3 1.3 -0.9 -0.5

MRKR Growth Metrics

    The 5 year net cashflow from operations growth rate now stands at -184.23%.
  • Its year over year net income to common stockholders growth rate is now at -38.74%.
  • Its 4 year net income to common stockholders growth rate is now at -820.21%.
Over the past 15 months, MRKR's revenue has gone up $6,946,111.

The table below shows MRKR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 6.946111 -25.52485 -35.8376
2022-06-30 2.99654 -24.39446 -41.34734
2022-03-31 2.206032 -30.44557 -43.00993
2021-12-31 1.24171 -27.27977 -41.87887
2021-09-30 0 -28.64046 -40.62278
2021-06-30 0 -26.36428 -35.56496

MRKR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MRKR has a Quality Grade of D, ranking ahead of 10.32% of graded US stocks.
  • MRKR's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
  • SIGA, TTNP, and PHIO are the stocks whose asset turnover ratios are most correlated with MRKR.

The table below shows MRKR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.000 NA -1.190
2021-03-31 0.008 1 -1.120
2020-12-31 0.010 1 -1.458
2020-09-30 0.015 1 -2.040
2020-06-30 0.014 1 -4.245
2020-03-31 0.004 1 -2127.159

MRKR Price Target

For more insight on analysts targets of MRKR, see our MRKR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.38 Average Broker Recommendation 1.38 (Strong Buy)

MRKR Stock Price Chart Interactive Chart >

Price chart for MRKR

MRKR Price/Volume Stats

Current price $0.32 52-week high $1.26
Prev. close $0.31 52-week low $0.25
Day low $0.29 Volume 48,600
Day high $0.33 Avg. volume 891,772
50-day MA $0.38 Dividend yield N/A
200-day MA $0.37 Market Cap 26.85M

Marker Therapeutics, Inc. (MRKR) Company Bio


Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.


MRKR Latest News Stream


Event/Time News Detail
Loading, please wait...

MRKR Latest Social Stream


Loading social stream, please wait...

View Full MRKR Social Stream

Latest MRKR News From Around the Web

Below are the latest news stories about MARKER THERAPEUTICS INC that investors may wish to consider to help them evaluate MRKR as an investment opportunity.

Here's Why Marker Therapeutics (NASDAQ:MRKR) Must Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | November 22, 2022

Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer

HOUSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for MT-601, a multi-tumor-associated antigen (multiTAA)-specific T cell product tar

Yahoo | November 22, 2022

Marker Therapeutics Reports Q3 2022 Operating and Financial Results

Company awarded $2 million U.S. FDA Orphan Products Grant to support Phase 2 ARTEMIS trial of its lead T cell therapy candidate MT-401 in patients with post-transplant AML Company awarded $2 million U.S. FDA Orphan Products Grant to support Phase 2 ARTEMIS trial of its lead T cell therapy candidate MT-401 in patients with post-transplant AML

GlobeNewswire | November 10, 2022

Marker Therapeutics GAAP EPS of -$0.08, revenue of $3.9M

Marker Therapeutics press release (MRKR): Q3 GAAP EPS of -$0.08.Revenue of $3.9M.

Seeking Alpha | November 10, 2022

MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Tops Revenue Estimates

MARKER THERAPEUTICS, INC. (MRKR) delivered earnings and revenue surprises of 38.46% and 393.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 10, 2022

Read More 'MRKR' Stories Here

MRKR Price Returns

1-mo -28.65%
3-mo 0.57%
6-mo N/A
1-year -73.98%
3-year -89.51%
5-year -88.15%
YTD -66.32%
2021 -34.47%
2020 -49.65%
2019 -48.11%
2018 41.58%
2017 1.03%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7331 seconds.